Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents

Journal of Ophthalmology

Volumn 2016, Issue , 2016, Pages

  Garoon, Robert B ^a,b   Coffee, Robert E ^b   Jiang, Lai ^c   Weng, Christina Y ^b   Carvounis, Petros E ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CULLEN EYE INSTITUTE   (United States)

^c Baylor College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84999885017     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2016/5282470     Document Type: Conference Paper

References (33)

1. S. E. Moss, R. Klein, B. E. K. Klein, "The 14-year incidence of visual loss in a diabetic population," Ophthalmology, vol. 105, no. 6, pp. 998-1003, 1998.
2. J. W. Y. Yau, S. L. Rogers, R. Kawasaki et al., "Global prevalence and major risk factors of diabetic retinopathy," Diabetes Care, vol. 35, no. 3, pp. 556-564, 2012.
3. D. R. Matthews, I.M. Stratton, S. J. Aldington, R. R. Holman, E. M. Kohner, "Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69," Archives of Ophthalmology, vol. 122, no. 11, pp. 1631-1640, 2004.
4. Diabetes Control and Complications Trial Research Group, "The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin dependent diabetes mellitus: the diabetes control and complications trial," Archives of Ophthalmology, vol. 113, no. 1, pp. 36-51, 1995.
5. T.-H. Chou, P.-C. Wu, J. Z.-C. Kuo, C.-H. Lai, C.-N. Kuo, "Relationship of diabetic macular oedema with glycosylated haemoglobin," Eye, vol. 23, no. 6, pp. 1360-1363, 2009.
6. E. Y. Chew, W. T. Ambrosius, M. D. Davis et al., "Effects of medical therapies on retinopathy progression in type 2 diabetes,"The New England Journal of Medicine, vol. 363, no. 3, pp. 233-244, 2010.
7. E. Y. Chew, M. D. Davis, R. P. Danis et al., "The effects ofmedical management on the progression of diabetic retinopathy in persons with type 2 diabetes.TheAction to Control Cardiovascular Risk in Diabetes Eye Study," Ophthalmology, vol. 121, pp. 2443-2451, 2014.
8. Early Treatment Diabetic Retinopathy Study Research Group, "Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1," Archives of Ophthalmology, vol. 103, no. 12, pp. 1796-1806, 1985.
9. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., "The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema," Ophthalmology, vol. 118, no. 4, pp. 615-625, 2011.
10. Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., "Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE," Ophthalmology, vol. 119, no. 4, pp. 789-801, 2012.
11. D. M. Brown, Q. D. Nguyen, D. M. Marcus et al., "Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results fromtwo phase III trials: RISE and RIDE," Ophthalmology, vol. 120, no. 10, pp. 2013-2022, 2013.
12. R. Rajendram, S. Fraser-Bell, A. Kaines et al., "A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3," Archives of Ophthalmology, vol. 130, no. 8, pp. 972-979, 2012.
13. M. J. Elman, N. M. Bressler, H. Qin et al., "Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema," Ophthalmology, vol. 118, no. 4, pp. 609-614, 2011.
14. M. J. Elman, A. Ayala, N. M. Bressler et al., "Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results," Ophthalmology, vol. 122, no. 2, pp. 375-381, 2015.
15. D. V. Do, Q. D. Nguyen, A. A. Khwaja et al., "Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment," JAMA Ophthalmology, vol. 131, no. 2, pp. 139-145, 2013.
16. J. F.Korobelnik,D.V.Do,U. Schmidt-Erfurth et al., "Intravitreal aflibercept for diabetic macular edema," Ophthalmology, vol. 121, no. 11, pp. 2247-2254, 2014.
17. J. A. Wells, A. R. Glassman, A. R. Ayala et al., "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema," The New England Journal ofMedicine, vol. 372, no. 13, pp. 1193-1203, 2015.
18. J. B. Jonas and A. S?ofker, "Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema," American Journal of Ophthalmology, vol. 132, no. 3, pp. 425-427, 2001.
19. Diabetic Retinopathy Clinical Research Network, "A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema," Ophthalmology, vol. 115, no. 9, pp. 1447-1459, 2008.
20. S. Jeon and W. K. Lee, "Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab," Retina, vol. 34, no. 8, pp. 1606-1611, 2014.
21. S. Matsuda, F. Gomi, Y. Oshima, M. Tohyama, Y. Tano, "Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress," Investigative Ophthalmology and Visual Science, vol. 46, no. 3, pp. 1062-1068, 2005.
22. Y.-S. Wang, W. Eichler, U. Friedrichs, S. Hoffmann, P. Wiedemann, "Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells," Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 240, no. 1, pp. 42-48, 2002.
23. H. Funatsu, H. Yamashita, H. Noma, T. Mimura, T. Yamashita, S. Hori, "Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema," American Journal of Ophthalmology, vol. 133, no. 1, pp. 70-77, 2002.
24. H. J. Sohn, D. H.Han, I. T. Kim et al., "Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema," American Journal of Ophthalmology, vol. 152, no. 4, pp. 686-694, 2011.
25. H. Ahmadieh, A. Ramezani, N. Shoeibi et al., "Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial," Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 4, pp. 483-489, 2008.
26. M. Soheilian, A. Ramezani, A. Obudi et al., "Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema," Ophthalmology, vol. 116, no. 6, pp. 1142-1150, 2009.
27. J.W. Lim, H. K. Lee, M. C. Shin, "Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial," Ophthalmologica, vol. 227, no. 2, pp. 100-106, 2012.
28. VassarStats: Website for statistical computation, May 2015, https://www.vassarstats.net.
29. S. Synek and B. Vojnikovi?c, "Intravitreal Bevacizumab with or without triamcinolone for refractory diabeticmacular oedema," Collegium Antropologicum, vol. 34, no. 2, pp. 99-103, 2010.
30. H. M. Marey and A. F. Ellakwa, "Intravitreal bevacizumab alone or combinedwith triamcinolone acetonide as the primary treatment for diabetic macular edema," Clinical Ophthalmology, vol. 5, no. 1, pp. 1011-1016, 2011.
31. Y.-S. Wang, X. Li, H.-Y. Wang, Z.-F. Zhang, M.-H. Li, X.-N. Su, "Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema," Chinese Medical Journal, vol. 124, no. 3, pp. 352-358, 2011.
32. N. Ferrara, "Vascular endothelial growth factor: basic science and clinical progress," Endocrine Reviews, vol. 25, no. 4, pp. 581-611, 2004.
33. A. N. Witmer, G. F. J. M. Vrensen, C. J. F. Van Noorden, R. O. Schlingemann, "Vascular endothelial growth factors and angiogenesis in eye disease," Progress in Retinal and Eye Research, vol. 22, no. 1, pp. 1-29, 2003.